Hyperfine, Inc.

NasdaqGM HYPR

Hyperfine, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -324.78%

Hyperfine, Inc. EBITDA Margin is -324.78% for the Trailing 12 Months (TTM) ending September 30, 2024, a 35.33% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Hyperfine, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -502.18%, a 65.68% change year over year.
Hyperfine, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -1,463.11%, a 58.96% change year over year.
Hyperfine, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -3,564.88%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: HYPR

Hyperfine, Inc.

CEO	Ms. Maria Sainz
IPO Date	Jan. 28, 2021
Location	United States
Headquarters	351 New Whitfield Street
Employees	131
Sector	Health Care
Industries Medical Instruments Augmented Reality (AR) Pharmaceuticals

Description

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

Key trends

Past 5 years